Francesca Barone

Francesca Barone holds the position of Chief Scientific Officer and has earned both an M.D. and a Ph.D., distinguishing her in the field of medical research. She has been actively involved in pioneering cancer treatments, presenting her work at several prestigious medical and scientific conferences. At the American Association for Cancer Research (AACR) Annual Meeting 2024, she presented a groundbreaking multimodal immunotherapy for inducing tertiary lymphoid structures, a novel approach for treating solid tumors. Additionally, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), she discussed the development of enLIGHTEN Alpha-201 herpes simplex viral vectors targeting the tumor microenvironment and a novel viral immunotherapeutic targeting the CD47/SIRPa axis, which demonstrated potent anti-tumor effects. Furthermore, she gave an oral presentation on the safety and survival outcomes of recurrent high-grade glioma patients treated with CAN-3110, a first-in-class ICP34.5 expressing oncolytic HSV1, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). She also presented findings on the detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 in patients with recurrent high-grade glioma at the 36th Annual Meeting of the Society for Neuro-Oncology (SNO). Her contributions have significantly advanced the understanding and development of therapeutic strategies in oncology.